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 In 2007, diabetes had aff ected 23.6 mil-
lion people in the United States, and the 
number was expected to increase signifi -
cantly. The disease is characterized by 
hyperglycemia in the setting of either 
inadequate insulin secretion or insulin 
resistance. Obesity is one of the major risk 
factors for type 2 diabetes. Diabetic neph-
ropathy is the number one cause of kid-
ney failure in the United States. 1 
Histologically, diabetic nephropathy is 
characterized by glomerular basement 
membrane thickening and mesangial 
expansion followed by nodular sclerosis 
( Figure 1c and d ). Clinically, micro- and, 
later, macroalbuminuria is observed, fol-
lowed by a decline in renal function. In 
diabetes, all three layers of the glomerular 
fi ltration barrier are aff ected: glomerular 
endothelial cells, mesangial cells, and 
glomerular epithelial cells (or podocytes). 
Endothelial-cell dysfunction is a common 
theme in all diabetic complications; at the 
same time, decreased podocyte numbers 
have  been shown to be a strong predictor 
of albuminuria and decline in renal func-
tion. 2,3 Since podocytes are the major 
source of vascular endothelial growth fac-
tor (VEGF) in glomeruli, and endothelial 
cells express the VEGF receptor, the 
cross-talk between podocytes and 
endothelial cells is likely to be abnormal 
in diabetes and might contribute to devel-
opment of diabetic nephropathy. 4,5 Podo-
cytes are particularly vulnerable to 
apoptosis in the setting of hyperglycemia, 
which could set up a vicious cycle causing 
both podocyte depletion and endothelial 
dysfunction. 3 
 Insulin is a hormone that binds to its 
receptor, a tyrosine kinase, which then 
phosphorylates insulin receptor sub-
strates (IRSs), the most well studied of 
which is IRS1. 6 IRSs then bind to phos-
phatidylinositol-3  -kinase (PI3K) or 
growth factor receptor-bound (GRB) pro-
teins, which recruit many other down-
stream targets, such as Akt, glycogen 
synthase kinase 3 (GSK3), endothelial 
nitric oxide synthase (eNOS), Ras, extra-
cellular signal-regulated kinase (ERK), 
and protein kinase C (PKC) to elicit 
wide-ranging effects including but not 
limited to glucose uptake, glycogenesis 
and lipogenesis, and cellular proliferation 7 
( Figure 1a ). PKC represents a group of 
serine / threonine kinases that are activated 
by a variety of chemical signals besides 
insulin, including calcium,  diacylglycerol, 
phosphatidylserine, and phorbol esters; 
the downstream eff ects are again wide-
ranging. Some isoforms of PKC appear to 
have downregulatory eff ects on insulin 
signaling, such as PKC-  , which sup-
presses the insulin-induced activation of 
Akt and eNOS via direct phosphorylation 
of IRS1. 8 Recent genetic studies indicate 
an association between PKC polymor-
phisms and the development of diabetic 
end-stage kidney disease. 9 Additionally, 
certain isoforms of PKC, including PKC-  , 
are persistently activated by hyperglyc-
emia, suggesting that there is perhaps 
overstimulation of PKC in diabetes. 
Th erefore it has been suggested that PKC 
plays a critical role in the development of 
diabetic complications, and inhibitors of 
the PKC pathway are currently being 
investigated as potential cures for dia-
betic complications. 
 Interestingly, insulin also seems to play 
a role in regulating the glomerular fi ltra-
tion barrier. Welsh and colleagues recently 
reported that podocyte-specifi c deletion 
of the insulin receptor leads to the rapid 
development of albuminuria and glomer-
ulosclerosis even in the setting of normo-
glycemia. 10,11 Since insulin is a major 
prosurvival factor for cells, the absence of 
insulin signaling probably resulted in 
podocyte death, contributing to the phe-
notype. While these studies highlight the 
key role of insulin signaling in diabetic 
nephropathy, yet, in most rodent models 
with type 1 diabetes (when insulin levels 
are almost undetectable), we do not 
observe rapid development of albuminu-
ria and glomerulosclerosis. In addition, 
although insulin resistance is almost uni-
versally observed in patients with type 2 
diabetes, there is never a complete loss of 
insulin signaling in patients. 
 To better understand insulin signaling 
in the glomerulus, Mima  et al. 12 (this 
issue) used two genetically distinct rat 
models of diabetes and obesity. Th eir ini-
tial experiments showed that insulin 
induces IRS1, Akt, eNOS, and GSK3a 
phosphorylation both in glomeruli and in 
tubules; however, the relative degree of 
IRS1, Akt, and GSK3 phosphorylation was 
decreased only in diabetic and obese 
glomeruli, not in the tubules. Th is  suggests 
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that insulin resistance specifi cally aff ects 
the IRS – PI3  K signaling pathway in 
glomeruli. Perhaps just as importantly, 
Mima  et al. 12 also showed that eNOS 
phosphorylation follows a similar glomer-
ulus-specifi c trend of depressed stimula-
tion aft er insulin, which could implicate 
the glomerulus as the initial target of dys-
function in diabetic nephropathy. Rubox-
istaurin, a specifi c inhibitor of PKC-  , 
however, can increase active Akt, eNOS, 
and GSK3 in diabetic and obese rats to 
almost normal levels aft er insulin, sug-
gesting that PKC-  may be responsible for 
the abnormal molecular signaling in insu-
lin resistance. 
 Mima  et al. 12 also found a signifi cant 
decrease in protein levels of IRS1, but not 
in mRNA levels of IRS1, in diabetic 
glomeruli of rats compared with their 
controls. Th ey also found that diabetic rats 
have increased levels of ubiquitin-associ-
ated IRS1, suggesting that diabetes leads 
to abnormal signaling that steers IRS1 
toward degradation. It seems that IRS1 
and PKC may be the culprits behind 
insulin resistance in diabetes, as both 
IRS1 overexpression and PKC inhibitor 
treatment were individually capable of 
partially overcoming the elevated-
glucose-induced suppression of Akt and 
eNOS in glomerular endothelial cells 
 in vitro . 
 Putting all this together, in diabetes and 
perhaps in metabolic syndrome, blunted 
eff ects of insulin can be observed in the 
glomerulus. Th e precise mechanism by 
which insulin resistance ultimately results 
in proteinuria and fi brosis is being eluci-
dated, as are the players necessary to 
mediate these changes. Th e research from 
Mima  et al. 12 suggests that glomerular 
endothelial cells exhibit changes in down-
stream insulin signaling that occur via a 
decrease in the availability of IRS1; the 
effects of this particular change are 
unknown, and whether or not this is nec-
essary for the development of diabetic 
nephropathy is unclear. Future studies 
should evaluate the consequences of IRS1 
depletion specifi cally within glomerular 
endothelial and other cells  in vivo . Also, 
although insulin-related second messen-
gers showed decreased phosphorylation 
in diabetic and obese rats, these results 
paint an unclear picture regarding in pre-
cisely which cell types these changes occur. 
Lastly, given the eff ect of PKC inhibitors 
on levels of other second messengers, 
there is still much to be said about what 
happens upstream of IRS and whether 
there are other unidentifi ed players. 
 Th e studies performed by Mima  et al. 12 
nevertheless represent an important step 
forward in understanding the develop-
ment of insulin resistance in the kidney 
and perhaps ultimately the pathway to 
end-stage kidney fi brosis. Diabetes and 
hyperglycemia probably have multiple 
eff ects on cell signaling and, when com-
bined with other genetic factors, result in 
varying degrees of abnormal kidney func-
tion. At least on the basis of what we know 
currently, PKC inhibitors have shown 
promise as therapeutic tools to combat the 
eff ects of diabetes. Although there are still 
many questions regarding the steps that 
lead to diabetic nephropathy, we now have 
several new places to begin our search for 
answers. 
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 During the fi rst three decades of clinical 
transplant practice (1960 – 1990), the 
great fear for both patient and clini-
cian was the occurrence of acute rejec-
tion. Th is process not only created the 
opportunity for sudden catastrophic graft  
loss but also set into motion the biologi-
cal processes leading to graft  scarring, 
glomerulopathy, and progressive renal 
dysfunction. Adding to this concern was 
the excess morbidity from opportunistic 
infection that frequently resulted from 
high-dose immunosuppression used to 
reverse such acute-rejection episodes. 
Today such events are distinctly uncom-
mon, thanks primarily to three advances 
in transplant practice: the development 
of sophisticated tissue typing and cross-
matching techniques that have virtually 
eliminated unintentional transplantation 
of kidneys into recipients presensitized 
to donor human leukocyte antigens; 
practices that limit excess immunosup-
pression coupled with more potent and 
selective anti-infective agents; and the 
widespread incorporation of calcineurin 
inhibitor (CNI) drugs into immuno-
suppressive regimens. However, the 
fall in both frequency and intensity of 
early acute rejections, the fi rst 6 months 
aft er transplantation, has not translated 
into improved long-term graft  survival 
beyond 1 – 2 years. 1 
 During the past decade there has been 
a major shift  in the focus of kidney trans-
plant research from the prevention of 
acute rejection to the recognition and tar-
geting of risk factors that associate with 
late graft  loss beyond 1 year. Although 
acute rejection is less formidable today, it 
nevertheless retains its role as an impor-
tant risk factor for late graft  loss. However, 
the demographic reality of an ever 
increasing age of donor kidneys, wait-
listed patients, and eventual transplant 
recipients has now introduced many chal-
lenges and stressors for long-term graft  
survival. 2 It is now apparent that the major 
causes of kidney graft  loss beyond 1 year 
aft er transplantation are progressive dete-
rioration of graft  function, oft en termed 
chronic allograft  nephropathy, the hall-
mark of which is histological evidence of 
tubular atrophy, interstitial fi brosis, and 
transplant glomerulopathy; and patient 
death from cardiovascular disease, oft en 
with a functioning kidney graft . What has 
also emerged is that many of the same risk 
factors associated with the former are also 
associated with the latter. Th ese include 
age; diabetes, both preexisting and occur-
ring aft er the transplantation; poorly con-
trolled hypertension; dyslipidemia; viral 
infections; and diminished allograft  func-
tion. In fact, renal dysfunction (estimated 
glomerular fi ltration rate (eGFR)   <  40 
cc / min) itself appears to be an independ-
ent risk factor for coronary heart disease 
and death. 3 
 A cruel irony that has accompanied 
the control of acute rejection via the 
widespread introduction of CNI drugs 
nearly 30 years ago has been their direct 
and indirect toxicity to the kidney. CNI 
nephrotoxicity appears to target the renal 
microcirculation by promoting pre-
glomerular vasoconstriction, as well as 
direct injury resulting in hyalinosis of 
blood vessels. In addition, CNIs appear 
to favor the progression of post-trans-
plantation hypertension, hyperglycemia, 
dyslipidemia, and oncogenesis, which 
are associated with late morbidity. 
Although variable in severity and oft en 
dose related, CNI nephrotoxicity con-
tributes to the decline in kidney function 
over time. 4 Th e pattern of injury is per-
haps best chronicled in non-transplant 
patients treated for autoimmune disease 
who lost 50 % of their native renal func-
tion and developed histological striped 
fi brosis aft er 2 years of continuous CNI 
use. 5 It has also been demonstrated by 
comparison of 2-year kidney biopsies 
that recipients treated with mycopheno-
late mofetil (MMF) and steroids and the 
mTOR inhibitor sirolimus in lieu of a 
CNI drug had diminished scarring and 
gene expression for fi brosis and tissue 
remodeling. 6 For these reasons, CNI 
dose reduction, elimination, or avoid-
ance has become the focus of numerous 
clinical kidney transplant trials with 
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 The search continues for the best role for mTOR inhibitor drugs in renal 
transplantation — principally to avoid or minimize the nephrotoxicity of 
the CNI class of immunosuppressive agents. The Spare the Nephron Trial 
describes the popular approach of early conversion from a CNI to the 
mTOR agent sirolimus for patients maintained on mycophenolate mofetil 
and steroids. At 1 – 2 years the glomerular filtration rate (GFR) was superior 
for the sirolimus group, with a loss of tolerability for about 20 % . 
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